Novartis Gains FDA Accelerated Approval for Kymriah in Relapsed or Refractory Follicular Lymphoma

Novartis's Kymriah (tisagenlecleucel) now carries an accelerated approval for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy, a label expansion that places confirmatory trial obligations squarely on the manufacturer's compliance calendar. For cell therapy plant heads and QA directors, the contingency language embedded in that approval is the operative detail: continued market authorization depends on verification of clinical benefit in post-marketing confirmatory trials.

The June 26, 2025 approval letter is the most recent in a sequence stretching back to Kymriah's original August 30, 2017 authorization, the first gene therapy approved in the United States. The current label covers three distinct indications: B-cell precursor ALL in patients up to 25 years of age that is refractory or in second or later relapse; relapsed or refractory large B-cell lymphoma in adults after two or more prior systemic therapies; and the newly expanded follicular lymphoma indication, which carries the accelerated approval qualifier. Primary central nervous system lymphoma remains an explicit limitation of use.

From a manufacturing and quality standpoint, each label iteration compounds the regulatory surface area for an autologous CAR-T product. Autologous cell therapy manufacturing operates under 21 CFR Part 211 and biologics-specific GMP expectations, with chain-of-identity controls, patient-specific batch release, and sterility assurance requirements that do not scale the way conventional biologics do. Any confirmatory trial protocol failure, or a post-marketing commitment that slips its agreed timeline, can trigger accelerated approval withdrawal proceedings, making trial execution a direct manufacturing readiness issue, not solely a clinical affairs concern.

The product also remains subject to a Risk Evaluation and Mitigation Strategy (REMS), reflecting the cytokine release syndrome and neurological toxicity profile inherent to CD19-directed CAR-T therapies. REMS-certified treatment centers must maintain the infrastructure and trained personnel to manage these adverse events, a requirement that constrains the commercial distribution network and informs site qualification decisions for any expanded indication rollout.

Demographic subgroup outcome data, referenced in Section 1.1 of the clinical reviewer memo, is available to QA and regulatory teams reviewing the supporting document package on the FDA product page, a resource that becomes relevant when assessing whether the confirmatory trial design adequately captures the patient population reflected in real-world manufacturing lots.

The measurable checkpoint ahead is the confirmatory trial readout for the follicular lymphoma indication, which will determine whether that accelerated approval converts to full authorization or is withdrawn.

Source: FDA Center for Biologics Evaluation and Research (CBER) via FDA.gov Vaccines, Blood and Biologics RSS Feed, June 24, 2026. Most recent approval letter dated June 26, 2025.